The MPN Hub spoke with Aaron Gerds, Cleveland Clinic Taussig Cancer Institute, Cleveland, US. We asked about the treatment of patients with myelofibrosis-associated anemia.

During this interview, Gerds discussed the burden and management of myelofibrosis-associated anemia. He explained its prevalence, prognostic importance, and multifactorial causes. Gerds also reviewed currently available therapies, combination strategies, and the need for further disease-modifying approaches.

This educational resource is independently supported by GSK. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.